This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Setting
Tertiary care, children's hospital. The study was carried out in Wisconsin, USA.
Dates to which data relate
The effectiveness and resource use data were collected between January 1993 and December 1995. The price year was not reported.
Source of effectiveness data
Effectiveness data were derived from a single study.
Link between effectiveness and cost data
Although no details were reported, the costing was presumably undertaken on the same patient sample as that used in the effectiveness study.
Study sample
No power calculations were reported. A total of 50 patients out of 103 neonates referred for rescue therapy during the study period were included in the study. Of these, 29 were admitted when inhaled nitric oxide was unavailable (due either to its permanent unavailability or to the concurrent use by other patients of the single delivery system at the institution), while the remainder (21 patients), were admitted when this delivery system was available. The final number of patients who met ECMO criteria was 21 and 16 for the control and intervention groups, respectively.
The analysis was based on the intention to treat principle. The primary health outcome measures were complicationfree survival and functional outcome, which was assessed by means of a ranked functional outcome index ranging from 4 (alive without apparent organ damage) to 0 (dead). Physiologic responses and safety data were also comparedfor the treatment group relative to their own baseline values. A logistic regression analysis was used in order to adjust for differences in patient characteristics between groups. Nevertheless, the groups were found to be comparable in terms of age, weight, gender, underlying diagnoses, oxygenation index, alveolar-arterial oxygen tension gradient, surfactant and high-frequency oscillatory ventilation administration before ECMO or nitric oxide, and evidence of persistence pulmonary hypertension of the newborn with extra pulmonary right to left shunt.
Effectiveness results
The survival rate without chronic lung disease (oxygen therapy at 28 days) and intracranial haemorrhage of any type was 10% and 69% (p=0.001) for the control and intervention groups, respectively. The relative risk ratio was 7.22 (95% CI: 1.85 -28.1). The ranked functional outcome index was 2.19 (+/-12.5) and 3.36 (+/-0.96) in the control and intervention groups, respectively (p=0.003). The logistic regression analysis showed that the only characteristic significantly associated with each health outcome measure in terms of complication-free survival and functional outcome was the availability of inhaled nitric oxide therapy.
Measure of benefits used in the economic analysis
The authors did not derive a summary measure of effectiveness for the economic analysis, but reported various outcome measures. The main health outcomes were complication-free survival and the ranked functional outcome index.
Direct costs
No details about the methodology employed in the cost analysis, data sources or the items included were provided. The authors referred to the total cost estimates as 'hospital costs'. The price year was not reported.
